JLINX

Accelerating Research to
Transform Human Health

Learn more

About Us

Johnson & Johnson Innovation, JLINX is a multifaceted initiative in Europe designed to identify and nurture early-stage companies who are actively pursuing research with the potential to transform human health.

Accelerating early-stage transformative innovation

We catalyze scientific advances by offering start-ups a spectrum of flexible ways to grow and collaborate across the European life science ecosystem.

Located in a fully dedicated facility on the Janssen Campus in Beerse, Belgium, Johnson & Johnson Innovation, JLINX fosters a creative start-up culture, provides access to select scientific talent and resources on the Janssen Campus and through the Johnson & Johnson Innovation network.

JLINX has a focus on human microbiome research, alongside other areas of innovation in pharmaceuticals and cross-disciplinary healthcare solutions.

Team

Johnson & Johnson Innovation, JLINX is a collaboration between Janssen Pharmaceutica NV and bioqube ventures, which will provide an experienced management team to run the day-to-day operations of JLINX, including managing the investment portfolio and relationships with external venture investors, involvement in identifying and securing new companies, and supporting the overall scale-up of the new initiative.

  • Tom Aelbrecht
    Head of the Janssen Campus Office
  • Debora Dumont
    Managing director of Bioqube Ventures
  • Nico Vandervelpen
    Managing director of Bioqube Ventures

Approach

Johnson & Johnson Innovation, JLINX will provides entrepreneurs with opportunities to share ideas and collaborate with each other while accessing a unique combination of resources including investment, infrastructure, and access to relevant internal and external scientific, technical and business expertise.

Operating at the Nexus of Science and Business

JLINX complements and extends the Johnson & Johnson Innovation network of initiatives to create a unique environment for scientist entrepreneurs to access capital, infrastructure, resources and expertise needed to build their businesses and advance scientific research and development for the benefit of patients.

JLINX accelerates early-stage transformative innovation, including a focus on the human microbiome as well as broader life-science research.

Nurtured Independence

Investment in promising transformative innovation through Johnson & Johnson Innovation, JLINX is venture-based and the Johnson & Johnson Family of Companies will not hold any specific rights to commercialized products by virtue of the JLINX relationship.

Johnson & Johnson Innovation will works closely with Bioqube Ventures, which will provide an experienced incubator management team to run day-to-day operations, including managing the investment portfolio and relationships with external venture investors, involvement in identifying and securing new companies, and supporting the overall scale-up of the new initiative.

Agility with Scale

Our model combines internal expertise with external entrepreneurial skills creating a start-up culture with selected resources, insights and expertise of a global healthcare leader to accelerate breakthroughs.

JLINX Community

bioqube.jpg caelus.jpg octimet.jpg s-biomedic.jpg etherna.jpg

News

  • JLINX Launch Event – Sparking Life Science Innovation

    Beerse, Belgium
    April 20, 2016

    Johnson & Johnson Innovation, Janssen Pharmaceutica and Bioqube Ventures host an event to launch JLINX, a first of its kind incubation and investment model in Europe.

  • Johnson & Johnson Innovation Launches a New Company Incubation Model Located at the Janssen Research & Development Campus in Beerse, Belgium

    Beerse, Belgium
    March 16, 2016

    Johnson & Johnson Innovation Launches a New Company Incubation Model Located at the Janssen Research & Development Campus in Beerse, Belgium

  • Bioqube ventures launches specialist investment firm and announces collaboration with Johnson & Johnson Innovation, JLINX

    Hasselt, Belgium
    March 16, 2016

    Bioqube ventures, a specialist life sciences investment firm that will focus on early-stage investments launches today. Bioqube ventures is an independent new venture that aims to identify, coach and nurture new investment opportunities. The bioqube ventures team is led by Debora Dumont and Nico Vandervelpen, co-founders and Managing Partners.

    Debora Dumont, Managing Partner bioqube ventures said: “Leveraging on our experience in venture capital and incubation models, bioqube ventures is well positioned to offer scientists and entrepreneurs access to funding, management, business and R&D expertise to enable early stage life sciences companies reach their full potential.”

Pages

Events

Contact Us

Make the Connection

JLINX is open to receive applications. We look forward to discussing opportunities to collaborate with you.

For general inquiries about JLINX, contact:
JLINX@ITS.JNJ.com

For investment inquiries, contact:
info@bioqubeventures.com

Telephone:
+32 (0) 14-621-500

Download the Johnson & Johnson
JLINX fact sheet.

Accelerators

Close
Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
mail@www.neomed.ca
www.neomed.ca
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.